Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of all the news that didn’t quite make the cut over the last week.
- Swedish research shows that testing childhood leukemia patients for specific epigenetic markers can predict which patients are most likely to relapse, which could help clinicians pick the best treatment for their patients.
- Researchers in Finland, along with nine project partners, have developed a device called ‘SniffPhone’ that can detect gastric cancer from a person’s breath.
- Israeli start-up Inspecto has invented a device that can detect a wide array of food contamination almost immediately, something that could be extremely useful in the food industry.
- In a development straight from science fiction, a team of Spanish, Russian and German scientists have developed a brain-computer interface that could result in telepathy becoming a reality in the future.
- Oxford Nanopore Technologies launched the ‘Flongle’: an adapter for the company’s portable and desktop DNA sequencers to allow quicker, smaller sequencing tests in a wider variety of environments.
- Pancreatic growths that contain certain oral bacteria species are more likely to become aggressive tumors in patients, Swedish scientists have found. This could provide a new biomarker that could let physicians detect pancreatic cancer earlier, before it causes a lot of damage.
Regulations and funding
- French biotech Theranexus will receive €6.2M from the French Investments for the Future program, managed by Bpifrance, to fund the development of its neurological disease targeting platform.
- French CAR T-cell therapy pioneer Cellectis is building manufacturing facilities in both North Carolina and Paris to scale up production and commercialization of the company’s cell therapies.
- Public Finnish biotech Herantis has raised €5.8M to help progress its Parkinson’s disease and lymphedema candidates towards the clinic.
- University College Dublin and Genomics Medicine Ireland announced a collaboration to research and develop precision medicines for a range of diseases such as autoimmune conditions and Alzheimer’s disease.
- Servier and Oncodesign have partnered to develop new drug candidates for Parkinson’s disease in a deal worth up to €320M to Oncodesign.
- Afyren and the Industrial Projects Fund, both based in France, are investing €50M to start a new biotech called Afyren Neoxy, which will focus on creating organic acids from sugar industry by-products for many uses including cosmetics, flavors and fragrances.
- French artificial intelligence company Iktos will partner with Merck to help the big pharma develop new drugs more rapidly and effectively using its technology.
Images via E. Resko